Table 1.
Summary of the 10 observational studies assessing the association between Protease Inhibitors based ART and preterm birth included in the meta-analysis
| First author, ref year | Design | Sample size | Setting/country | Comparison regime | Time of initiation during pre/before pre | PTD type | AOR (95 % CI) |
|---|---|---|---|---|---|---|---|
| Cotter AM et al., 2006 [8] | Prospective | 999 | Miami, Florida, USA | Combination without PI | <12wk,12–23wk, 3rd trimester | <37wk | 1.8 (1.1,3.0) |
| Powis KM, et al., 2011 [23] | Randomized | 730 | Botswana | Triple NRTI based ARTwout PI | Between 26 and 34 weeks | <37wk | 2.02 (1.25–3.27) |
| Grosch-Woerner I et al., 2007 [11] | Prospective | 183 | Germany & Austria | Mono therapy | >2wks before conception) or during pregnancy | <36wk | 3.40 (1.13–10.2) |
| Schulte J, et al., 2012 [12] | Prospe | 8793 | Atalanta, Georgia | 2drugs | 26–42wk | 37 | 1.21 (1.04–1.40) |
| Watts DH et al., 2013 [24] | Cohort | 1869 | USA | Mono or dual therapy | 1st -3rd trimester | 37 | 1.49 (0.83,2.66) |
| Tuomala RE et al., 2002 [13] | Trial & cohort | 2123 | Boston USA | Combination without PI | 1st -3rd trimeste | 37 | 1.80 (0.94–3.43) |
| Patel K et al.,2011 [22] | Prospe cohort | 777 | USA | Mono/combination without PI | 1st -3rd trimeste | 37 | 1.29 (0.77, 2.15) |
| Szylda EG, et al., 2006 [14] | Prospective cohort | 681 | Argentina, Bahamas,Brazi, Mexico | 1–2 NRTI | Before/during pregnancy | 37 | 1.1 (0.5–2.8) |
| Townsend CL et al., 2007 [15] | Surveillance | 5009 | UK | Combination | Before/during pregnancy | 37 | 0.96 (0.78,1.19) |
| Hankin C et al., 2003 [16] | Prospecti | 2326 | 9 EU country | No ART | >> | 37 | 4.14 (2.36,7.23) |